This site is intended for healthcare professionals

Merck announces positive topline results from two additional phase III adult studies evaluating V 114, Merck’s investigational 15-valent pneumococcal conjugate vaccine.

Read time: 1 mins
Last updated:16th Mar 2021
Published:21st Oct 2020
Condition: Pneumococcal Disease
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest